Targeting a specific cancer marker in pancreatic cancer
Targeting Disease Specific Tn Antigen in Pancreatic Cancer
This study is looking for new treatments for pancreatic cancer that can better target the cancer cells, helping to boost the immune system's ability to fight the disease, especially for those whose cancer is more advanced.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11047385 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of cancer that often presents at an advanced stage. The study aims to develop new targeted therapies that specifically attack cancer cells expressing unique carbohydrate antigens known as Tn and Sialyl Tn. These antigens are linked to poor prognosis and are not typically found in healthy pancreatic tissue. By using a novel monoclonal antibody designed to target these antigens, the research seeks to enhance the immune response against the cancer and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have advanced or metastatic disease.
Not a fit: Patients with early-stage pancreatic cancer or those whose tumors do not express Tn or Sialyl Tn antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar cancer-associated antigens, indicating potential for success with this novel approach.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Radhakrishnan, Prakash — University of Nebraska Medical Center
- Study coordinator: Radhakrishnan, Prakash
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.